- Home
- CDNL vs KURA Comparison
CDNL vs KURA Comparison
Compare CDNL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDNL | KURA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 1.1B |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CDNL | KURA |
|---|---|---|
| Price | $38.10 | $12.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $38.00 | $25.56 |
| AVG Volume (30 Days) | 829.4K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $456,045,369.00 | $67,482,000.00 |
| Revenue This Year | $50.30 | $28.28 |
| Revenue Next Year | $8.41 | $106.37 |
| P/E Ratio | $72.11 | ★ N/A |
| Revenue Growth | ★ 44.69 | 25.24 |
| 52 Week Low | $21.98 | $7.36 |
| 52 Week High | $96.40 | $13.90 |
Technical Indicators
Market Signals| Indicator | CDNL | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 57.45 |
| Support Level | $23.33 | $7.96 |
| Resistance Level | $66.73 | $13.90 |
| Average True Range (ATR) | 2.44 | 0.63 |
| MACD | 0.52 | 0.01 |
| Stochastic Oscillator | 32.36 | 47.77 |
Price Performance
Historical ComparisonAbout CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.